Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Alvarez & Marsal are most popular: within Insolvency/Bankruptcy/Re-Structuring, Criminal Law, Litigation and Mediation & Arbitration topic(s) At the federal level, the US has adopted a pro-innovation posture that largely defers to agencies for specific enforcement guidance. Meanwhile, certain states have advanced AI regulations focused on consumer protection and workplace practices, creating a complex and, at times, contradictory enforcement environment.
Alvarez & Marsal are most popular: within Insolvency/Bankruptcy/Re-Structuring, Criminal Law and Law Practice Management topic(s) US pharmaceutical companies have long been a dominant force in global foreign direct investment (FDI), contributing around 25% of outbound FDI in the sector and over half of global pharmaceutical research and development (R&D) spending.1 This leadership is rooted in the strong profitability of the US market.
MFN may never become law, but its signal still matters The industry is still parsing the implications of the new MFN framework established by May's Executive Order. While practical policy details remain undefined, the signal is unmistakable: the administration wants to bring pharma to the table on drug pricing. The real question is how the industry responds. Does it see MFN as a threat that it must navigate or as an opportunity to lead?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
